In October of this year, a 63-year-old patient with a diagnosis of multiple myeloma underwent transplantation of his own hematopoietic stem cells (ASCT) at the General University Hospital (VFN) in Prague 2000. This procedure will allow the administration of significantly higher doses of chemotherapy, which could normally be fatal, and significantly shortens the time of hematopoietic depression in the patient.

The process of the patient's own donor significantly reduces the time of postchemotherapeutic suppression of hematopoiesis and reduces the hematological toxicity of administered chemotherapy, which would otherwise lead to an extremely long period of bone marrow aplasia with a number of complications. Hematopoietic stem cell transfer support thus allows for the administration of significantly higher doses of chemotherapy.

20% of all ASCTs in the Czech Republic are performed at the General Hospital

"The first autologous transplant was performed at the General Hospital in 1993," the head of the 1st internal clinic - the clinic of hematology of the General Hospital and the 1st Medical Faculty of Charles University prof. MUDr. Marek Trneny, CSc. and calculates: “Since then, the number of performed ASCTs has been constantly growing, until it has stabilized at 80 to 90 performances per year in the last decade.

1662 patients were transplanted

The total number of 2000 ASCTs includes 1662 patients, 334 of whom underwent the procedure two or three times. "Patients with multiple myeloma and malignant lymphomas (non-Hodgkin’s and Hodgkin’s), "Explains MUDr. Eva Konířová, doctor of the 1st internal clinic of the General Hospital and the 1st Medical Faculty of Charles University and supplies: “Uncommon indications are patients with solid malignancies (historically mainly breast cancers, currently mainly medulloblastoma brain tumors) and autoimmune diseases. These used to be mainly multiple sclerosis, and more recently systemic sclerosis."

For more information, see press release.